IRIS Accounts Production v24.3.2.46 09309176 Board of Directors 1.10.23 30.9.24 30.9.24 0 0 false true false false true false Ordinary 0.0100 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh093091762023-09-30093091762024-09-30093091762023-10-012024-09-30093091762022-09-30093091762022-10-012023-09-30093091762023-09-3009309176ns15:EnglandWales2023-10-012024-09-3009309176ns14:PoundSterling2023-10-012024-09-3009309176ns10:Director12023-10-012024-09-3009309176ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3009309176ns10:SmallEntities2023-10-012024-09-3009309176ns10:AuditExempt-NoAccountantsReport2023-10-012024-09-3009309176ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3009309176ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3009309176ns10:FullAccounts2023-10-012024-09-3009309176ns10:OrdinaryShareClass12023-10-012024-09-3009309176ns10:Director22023-10-012024-09-3009309176ns10:Director32023-10-012024-09-3009309176ns10:Director42023-10-012024-09-3009309176ns10:Director52023-10-012024-09-3009309176ns10:Director62023-10-012024-09-3009309176ns10:RegisteredOffice2023-10-012024-09-3009309176ns5:CurrentFinancialInstruments2024-09-3009309176ns5:CurrentFinancialInstruments2023-09-3009309176ns5:ShareCapital2024-09-3009309176ns5:ShareCapital2023-09-3009309176ns5:SharePremium2024-09-3009309176ns5:SharePremium2023-09-3009309176ns5:RetainedEarningsAccumulatedLosses2024-09-3009309176ns5:RetainedEarningsAccumulatedLosses2023-09-3009309176ns5:PlantMachinery2023-10-012024-09-3009309176ns5:ComputerEquipment2023-10-012024-09-3009309176ns5:PlantMachinery2024-09-3009309176ns5:ComputerEquipment2024-09-3009309176ns10:OrdinaryShareClass12024-09-30
REGISTERED NUMBER: 09309176 (England and Wales)













Unaudited Financial Statements

for the Year Ended 30 September 2024

for

Heart Biotech Nano Limited

Heart Biotech Nano Limited (Registered number: 09309176)






Contents of the Financial Statements
for the Year Ended 30 September 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Heart Biotech Nano Limited

Company Information
for the Year Ended 30 September 2024







DIRECTORS: M A Ishak-Hanna
S S Khouri
M C Radford
I A Richardson
M H Yacoub
F W White





REGISTERED OFFICE: 17 North Drive
Littleton
Winchester
SO22 6QA





REGISTERED NUMBER: 09309176 (England and Wales)





ACCOUNTANTS: Clive Owen LLP
Chartered Accountants
Kepier House
Belmont Business Park
Durham
DH1 1TW

Heart Biotech Nano Limited (Registered number: 09309176)

Balance Sheet
30 September 2024

2024 2023
Notes £    £   
FIXED ASSETS
Tangible assets 4 13,662 -

CURRENT ASSETS
Debtors 5 - 1

CREDITORS
Amounts falling due within one year 6 (160,778 ) (994,643 )
NET CURRENT LIABILITIES (160,778 ) (994,642 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(147,116

)

(994,642

)

CAPITAL AND RESERVES
Called up share capital 7 110 1
Share premium 794,917 -
Retained earnings (942,143 ) (994,643 )
SHAREHOLDERS' FUNDS (147,116 ) (994,642 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 April 2025 and were signed on its behalf by:





F W White - Director


Heart Biotech Nano Limited (Registered number: 09309176)

Notes to the Financial Statements
for the Year Ended 30 September 2024

1. STATUTORY INFORMATION

Heart Biotech Nano Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

There were no material departures from that standard.

The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.

Going concern
The company is yet to make any sales, however, this is in line with the early expectations of the business which continues to receive the support of its directors and group companies. The group companies will continue to make available financial support as may be required for the 12 months from the date of signing these financial statements.

The financial statements are prepared on the going concern basis which assumes that the company will continue to trade. If the company is unable to continue to trade, adjustments would be required to reduce the value of assets to their recoverable amounts, to provide for any further liabilities that might arise and to analyse long term liabilities as current liabilities.

Related party transactions
The company has taken advantage of exemption, under the terms of the Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with companies under common control.

There were no related party transactions other than those concluded under normal market conditions.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 20% on cost
Computer equipment - 33% on cost

Tangible fixed asses are measured at cost less accumulated depreciation and impairment.

Financial instruments
Basic financial instruments are recognised at amortised cost with changes recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Heart Biotech Nano Limited (Registered number: 09309176)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
COST
Additions 11,818 2,099 13,917
At 30 September 2024 11,818 2,099 13,917
DEPRECIATION
Charge for year 197 58 255
At 30 September 2024 197 58 255
NET BOOK VALUE
At 30 September 2024 11,621 2,041 13,662

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed by group undertakings - 1

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed to group undertakings - 992,843
Accruals and deferred income 160,778 1,800
160,778 994,643

Heart Biotech Nano Limited (Registered number: 09309176)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
110,000 Ordinary £0.00 1 110 1

8. ULTIMATE CONTROLLING PARTY

The ultimate parent company is Heart Biotech Holdings Limited, a company incorporated in England.
The registered office is 17 North Drive, Littleton, Winchester, SO22 6QA.